

Donald L Lamm

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3285921/donald-l-lamm-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36
papers

4,634
citations

25
h-index

39
g-index

39
ext. papers

5,395
ext. citations

10.3
avg, IF

4.81
L-index

#	Paper	IF	Citations
36	MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY. <i>Journal of Urology</i> , 2000 , 163, 1124-1129	2.5	842
35	Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials. <i>Journal of Urology</i> , 2002 , 168, 1964-1970	2.5	807
34	A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guërin for transitional-cell carcinoma of the bladder. <i>New England Journal of Medicine</i> , 1991 , 325, 1205-9	59.2	502
33	Management of stage T1 tumors of the bladder: International Consensus Panel. <i>Urology</i> , 2005 , 66, 108-256		326
32	Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical Treatment. <i>Journal of Urology</i> , 1996 , 156, 363-367	2.5	247
31	Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. <i>Journal of Urology</i> , 1980 , 124, 38-40	2.5	236
30	A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. <i>Journal of Urology</i> , 2011 , 186, 2158-67	2.5	197
29	Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1935-44	2.2	183
28	Megadose vitamins in bladder cancer: a double-blind clinical trial. <i>Journal of Urology</i> , 1994 , 151, 21-6	2.5	135
27	Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1995 , 1, 119-26	2.8	102
26	Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. <i>Nature Reviews Urology</i> , 2015 , 12, 225-35	5.5	101
25	Bacillus Calmette-Guërin with or without interferon β and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , 2010 , 184, 1915-9	2.5	95
24	An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 440-447	2.8	85
23	Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. <i>Journal of Urology</i> , 2014 , 191, 20-7	2.5	76
22	BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. <i>Nature Reviews Urology</i> , 2017 , 14, 244-255	5.5	69
21	Immunotherapy of murine transitional cell carcinoma. <i>Journal of Urology</i> , 1982 , 128, 1104-8	2.5	68
20	Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , 2014 , 192, 305-15	2.5	66

19	Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy Associated Adverse Events. <i>European Urology Supplements</i> , 2008 , 7, 667-674	0.9	64
18	Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). <i>BJU International</i> , 2013 , 112, 742-50	5.6	61
17	Bladder cancer, 1996. <i>Ca-A Cancer Journal for Clinicians</i> , 1996 , 46, 93-112	220.7	54
16	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma 2017 , 5, 68		48
15	Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. <i>European Urology</i> , 2000 , 37 Suppl 3, 41-4	10.2	48
14	Superficial bladder cancer therapy. <i>Scientific World Journal, The</i> , 2004 , 4 Suppl 1, 387-99	2.2	36
13	Long term protection in bladder cancer following intravesical immunotherapy. <i>Journal of Urology</i> , 1984 , 132, 570-3	2.5	34
12	Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 35.e21-30	2.8	31
11	Clinical Practice Recommendations for the Management of NonMuscle Invasive Bladder Cancer. <i>European Urology Supplements</i> , 2008 , 7, 651-666	0.9	24
10	A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guérin for superficial bladder cancer. <i>Journal of Urology</i> , 1990 , 144, 65-7	2.5	21
9	Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk NonMuscle-Invasive Bladder Cancer. <i>European Urology Supplements</i> , 2010 , 9, 715-734	0.9	19
8	Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG). <i>BJU International</i> , 2020 , 125, 497-505	5.6	18
7	Improving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression in Superficial Bladder Cancer. <i>European Urology Supplements</i> , 2006 , 5, 654-659	0.9	10
6	Pelvic recurrence after radical cystectomy: a call to arms. <i>BJU International</i> , 2015 , 116, 172-3	5.6	6
5	Tumor implantation: a rare but potentially preventable cause of death in cystectomy patients. <i>Canadian Journal of Urology</i> , 2010 , 17, 5216-8	0.8	4
4	Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. <i>Eur Urol</i> 2009;56:247-56. <i>European Urology</i> , 2010 , 57, e7-9; author reply e10-1	10.2	2
3	A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment. <i>Vaccine</i> , 2021 , 39, 7308-7318	4.1	2
2	Re: Richard J. Sylvester, Willem Oosterlinck, Sten Holmang, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2015.05.050 . <i>European Urology</i> , 2015 , 68, e127	10.2	

1 Bacillus Calmette-Guérin Immunotherapy of Genitourinary Cancer **2007**, 29-42